- 関
- antilipemic agent、antilipemic drug、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering、lipid-lowering agent、lipid-lowering drug
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/07/02 19:03:05」(JST)
[Wiki en表示]
Hypolipidemic agents, or antihyperlipidemic agents, are a diverse group of pharmaceuticals that are used in the treatment of hyperlipidemias. They are called lipid-lowering drugs.
Contents
- 1 Classes of hypolipidemic drugs
- 1.1 Established
- 1.2 Investigational
- 2 References
- 3 See also
Classes of hypolipidemic drugs
There are several classes of hypolipidemic drugs. They may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower the "bad cholesterol" low density lipoprotein (LDL) more so than others, while others may preferentially increase high density lipoprotein (HDL), "the good cholesterol". Clinically, the choice of an agent will depend on the patient's cholesterol profile, cardiovascular risk, and the liver and kidney functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the evidence-based guideline from the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII).
Established
- Statins are particularly well suited for lowering LDL, the cholesterol with the strongest links to vascular diseases. In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. There is a risk of severe muscle damage (myopathy & rhabdomyolysis) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85.[1]
- Fibrates are indicated for hypertriglyceridemia. Fibrates typically lower triglycerides by 20% to 50%. Level of the good cholesterol HDL is also increased. Fibrates may decrease LDL, though generally to a lesser degree than statins. Similar to statins, there is a risk of severe muscle damage (myopathy & rhabdomyolysis).
- niacin, like fibrates, is also well suited for lowering triglycerides by 20–50%. It may also lower LDL by 5–25% and increase HDL by 15–35%. Niacin may cause hyperglycemia and may also cause liver damage. The niacin derivative acipimox is also associated with a modest decrease in LDL.
- Bile acid sequestrants (resins, e.g. cholestyramine) are particularly effective for lowering LDL-C by sequestering the cholesterol-containing bile acids released into the intestine and preventing their reabsorption from the intestine. It decreases LDL by 15–30% and raises HDL by 3–5%, with little effect on triglycerides but can cause a slight increase. Bile acid sequestrants may cause gastrointestinal problems and may also reduce the absorption of other drugs and vitamins from the gut.
- ezetimibe (Zetia) is a selective inhibitor of dietary cholesterol absorption.
- lomitapide (Juxtapid) is a microsomal triglyceride transfer protein (MTP) inhibitor.
- phytosterols may be found naturally in plants. Similar to ezetimibe, phytosterols reduce the absorption of cholesterol in the gut. Hence, they are most effective when consumed with meals. However, the precise mechanism of action of phytosterols differs from ezetimibe.
- orlistat (Xenical): Its primary function is to prevent the absorption of about 30% of fats from the human diet, thereby reducing caloric intake. A drug designed to treat obesity, it works by inhibiting Pancreatic lipase, an enzyme that breaks down triglycerides in the intestine.
Investigational
Investigational classes of hypolipidemic agents:
- CETP inhibitors (cholesteryl ester transfer protein), 1 candidate is in trials. It is expected that these drugs will mainly increase HDL while lowering LDL;
- Squalene synthase inhibitor;
- ApoA-1 Milano
- succinobucol(AGI-1067), a novel antioxidant, failed a phase 3 trial
- Apoprotein-B inhibitor Mipomersen (approved by the FDA in 2013 homozygous familial hypercholesterolemia.[2][3]).
- PCSK9 Monoclonal antibody inhibitors [4][5]
References
- ^ AMDA – The Society for Post-Acute and Long-Term Care Medicine (February 2014), "Ten Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (AMDA – The Society for Post-Acute and Long-Term Care Medicine), retrieved 20 April 2015 .
- ^ Pollack, Andrew (29 January 2013) F.D.A. Approves Genetic Drug to Treat Rare Disease The New York Times, Retrieved 31 January 2013
- ^ Staff (29 January 2013) FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder U.S. Food and Drug Administration, Retrieved 31 January 2013
- ^ Koren MJ, Scott R, Kim JB et al Lancet 2012; 380:1995-2006
- ^ Gugliano RP, Desai NR, Kohli P et al Lancet 2012; 380:2007-17
See also
Lipid modifying agents (C10)
|
|
GI tract |
Cholesterol absorption inhibitors, NPC1L1 |
|
|
Bile acid sequestrants/resins (LDL) |
- Colestyramine
- Colestipol
- Colestilan
- Colextran
- Colesevelam
|
|
|
Liver |
Statins (HMG-CoA reductase, LDL) |
- Simvastatin#
- Atorvastatin
- Fluvastatin
- Lovastatin
- Mevastatin
- Pitavastatin
- Pravastatin
- Rosuvastatin
- Cerivastatin‡
|
|
Niacin and derivatives (HDL and LDL) |
- Niceritrol
- Niacin
- Nicofuranose
- Aluminium nicotinate
- Nicotinyl alcohol
- Acipimox
|
|
MTTP inhibitors (VLDL) |
- Dirlotapide
- Lomitapide
- Mitratapide
|
|
|
Blood vessels |
Fibrates (PPAR) |
- Clofibrate‡
- Bezafibrate
- Aluminium clofibrate
- Gemfibrozil
- Fenofibrate
- Simfibrate
- Ronifibrate
- Ciprofibrate
- Etofibrate
- Clofibride
- Clinofibrate
|
|
CETP inhibitors (HDL) |
- Anacetrapib†
- Dalcetrapib§
- Evacetrapib§
- Torcetrapib§
|
|
|
Combinations |
- Niacin/lovastatin
- Niacin/simvastatin
- Ezetimibe/simvastatin
- Ezetimibe/atorvastatin
- Niacin/laropiprant
|
|
Other |
- Dextrothyroxine‡
- Probucol
- Tiadenol
- Benfluorex
- Meglutol
- Omega-3-triglycerides
- Magnesium pyridoxal 5-phosphate glutamate
- Policosanol
- Lapaquistat§
- Mipomersen
- Alipogene tiparvovec
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- The hypolipidemic activity of chitosan nanopowder prepared by ultrafine milling.
- Zhang W, Zhang J, Jiang Q, Xia W.SourceState Key Laboratory of Food Science and Technology, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, 214122, China.
- Carbohydrate polymers.Carbohydr Polym.2013 Jun 5;95(1):487-91. doi: 10.1016/j.carbpol.2013.02.037. Epub 2013 Mar 4.
- The hypolipidemic activities of high and low molecular weights of chitosan nanopowders (HMW-chitosan-NP: 315kDa; LMW-chitosan-NP: 51kDa) prepared by ultrafine milling were evaluated in rats. The results showed that the hypolipidemic activity of chitosan nanopowder was better than ordinary chitosan,
- PMID 23618297
- Antiobesity potential of ursolic acid stearoyl glucoside by inhibiting pancreatic lipase.
- Kazmi I, Afzal M, Rahman S, Iqbal M, Imam F, Anwar F.SourcePacific University, Udaipur-313024, Rajasthan, India; Siddhartha Institute of Pharmacy, Dobachi, Near IT Park, Dehradun-248001, Uttarakhand, India.
- European journal of pharmacology.Eur J Pharmacol.2013 Jun 5;709(1-3):28-36. doi: 10.1016/j.ejphar.2013.02.032. Epub 2013 Mar 13.
- The present study was designed to evaluate the hypolipidemic effect of ursolic acid stearoyl glucoside (UASG) in high-fat diet-induced obesity. Two in vivo experiments such as high-fat diet-induced obesity mice model and lipid emulsion tolerance test in normal rats were performed. In vitro inhibitio
- PMID 23500199
Japanese Journal
- Dietary Effects of Oxidized Eicosapentaenoic Acid (EPA) and Intact EPA on Hepatic Steatosis Induced by a High-sucrose Diet and Liver-X-receptor α Agonist in Mice
- Gut Microbial Fatty Acid Metabolites Reduce Triacylglycerol Levels in Hepatocytes.
Related Links
- Hypolipidemic agents, or antihyperlipidemic agents, are a diverse group of pharmaceuticals that are used in the treatment of hyperlipidemias. They are called lipid-lowering drugs. Contents. 1 Classes of hypolipidemic drugs. 1.1 Established ...
- hypolipidemic /hy·po·lip·id·emic/ (-lip″id-ēm´ik) promoting the reduction of lipid concentrations in the serum. hypolipidemic [hi″po-lip″ĭ-de´mik]. promoting the reduction of lipid concentrations in the serum. hypolipidemic. promoting the ...
Related Pictures
![Hypolipidemic Drugs, Aspirin 81 Mg Tablet](https://1mg.info/0/9/h/2228.jpg)
![Entity page for hypolipidemic](https://1mg.info/0/9/h/2229.jpg)
![Britannica.com](https://1mg.info/0/9/h/2230.jpg)
![Hypolipidemic Drugs](https://1mg.info/0/9/h/2231.jpg)
![of the hypoglycemic, hypolipidemic](https://1mg.info/0/9/h/2232.jpg)
★リンクテーブル★
[★]
- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering agent
[★]
- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering drug
[★]
- 関
- antilipemic agent、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering agent、lipid-lowering drug
[★]
- 関
- antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemic drug、hypolipidemics、lipid-lowering agent、lipid-lowering drug
[★]
- 英
- lipid-lowering、hypolipidemic
- 関
- 抗高脂血症薬、脂質低下性、脂質低下薬
[★]
- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemics、lipid-lowering agent、lipid-lowering drug
[★]
- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic drug、hypolipidemics、lipid-lowering agent、lipid-lowering drug
[★]
抗高脂血症薬
- 関
- antilipemic agent、antilipemic drug、hypolipidemic、hypolipidemic agent、hypolipidemic drug、lipid-lowering agent、lipid-lowering drug